Neuronetics (STIM) Competitors $3.57 +0.03 (+0.85%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.53 -0.04 (-1.23%) As of 07/11/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STIM vs. KMTS, SIBN, IRMD, CBLL, EMBC, BBNX, AVNS, BVS, KIDS, and RXSTShould you be buying Neuronetics stock or one of its competitors? The main competitors of Neuronetics include Kestra Medical Technologies (KMTS), SiBone (SIBN), iRadimed (IRMD), CeriBell (CBLL), Embecta (EMBC), Beta Bionics (BBNX), AVANOS MEDICAL (AVNS), Bioventus (BVS), OrthoPediatrics (KIDS), and RxSight (RXST). These companies are all part of the "medical equipment" industry. Neuronetics vs. Its Competitors Kestra Medical Technologies SiBone iRadimed CeriBell Embecta Beta Bionics AVANOS MEDICAL Bioventus OrthoPediatrics RxSight Kestra Medical Technologies (NASDAQ:KMTS) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk. Which has stronger earnings and valuation, KMTS or STIM? Kestra Medical Technologies has higher earnings, but lower revenue than Neuronetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKestra Medical TechnologiesN/AN/AN/AN/AN/ANeuronetics$74.89M3.15-$43.71M-$1.31-2.73 Do insiders & institutionals believe in KMTS or STIM? 53.6% of Neuronetics shares are owned by institutional investors. 8.7% of Neuronetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate KMTS or STIM? Kestra Medical Technologies currently has a consensus target price of $27.50, indicating a potential upside of 84.44%. Neuronetics has a consensus target price of $5.50, indicating a potential upside of 54.06%. Given Kestra Medical Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Kestra Medical Technologies is more favorable than Neuronetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kestra Medical Technologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Neuronetics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer KMTS or STIM? In the previous week, Kestra Medical Technologies had 5 more articles in the media than Neuronetics. MarketBeat recorded 7 mentions for Kestra Medical Technologies and 2 mentions for Neuronetics. Neuronetics' average media sentiment score of 0.93 beat Kestra Medical Technologies' score of 0.89 indicating that Neuronetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kestra Medical Technologies 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Neuronetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KMTS or STIM more profitable? Kestra Medical Technologies has a net margin of 0.00% compared to Neuronetics' net margin of -53.67%. Kestra Medical Technologies' return on equity of 0.00% beat Neuronetics' return on equity.Company Net Margins Return on Equity Return on Assets Kestra Medical TechnologiesN/A N/A N/A Neuronetics -53.67%-174.15%-38.41% SummaryKestra Medical Technologies beats Neuronetics on 7 of the 11 factors compared between the two stocks. Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STIM vs. The Competition Export to ExcelMetricNeuroneticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$234.04M$6.82B$5.60B$9.11BDividend YieldN/A1.25%5.24%4.02%P/E Ratio-2.7324.8927.9620.25Price / Sales3.1565.26430.5799.61Price / CashN/A20.9237.4658.16Price / Book6.264.648.045.49Net Income-$43.71M$174.76M$3.18B$250.27M7 Day Performance4.85%-1.00%3.63%4.75%1 Month Performance-6.30%-1.49%4.04%7.64%1 Year Performance90.91%4.27%29.56%16.34% Neuronetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STIMNeuronetics1.7056 of 5 stars$3.57+0.8%$5.50+54.1%+90.9%$234.04M$74.89M-2.73180News CoverageKMTSKestra Medical TechnologiesN/A$14.75-5.9%$27.50+86.4%N/A$804.64M$52.64M0.00300SIBNSiBone4.0043 of 5 stars$18.01-2.5%$22.50+24.9%+16.8%$787.09M$167.18M-28.14350Positive NewsIRMDiRadimed4.9243 of 5 stars$59.02-4.5%$72.00+22.0%+23.7%$785.79M$73.24M38.08110CBLLCeriBell2.5881 of 5 stars$17.20-9.1%$32.14+86.9%N/A$684.19M$65.44M0.00N/ANews CoverageInsider TradeEMBCEmbecta4.7526 of 5 stars$10.03-2.8%$19.33+92.8%-18.0%$603.13M$1.08B11.142,100News CoveragePositive NewsBBNXBeta BionicsN/A$13.40-0.9%$23.44+75.0%N/A$586.18M$65.12M0.00294AVNSAVANOS MEDICAL2.609 of 5 stars$11.87-3.9%N/A-43.6%$571.11M$687.80M-1.422,227News CoverageBVSBioventus2.984 of 5 stars$6.82-2.8%$13.75+101.6%+5.9%$560.22M$567.70M-11.181,200News CoverageKIDSOrthoPediatrics4.2856 of 5 stars$21.24-5.5%$35.83+68.7%-34.0%$545.96M$204.73M-12.14200RXSTRxSight2.2382 of 5 stars$12.43-4.8%$37.90+204.9%-83.9%$530.31M$139.93M-18.55220Trending NewsAnalyst Forecast Related Companies and Tools Related Companies KMTS Competitors SIBN Competitors IRMD Competitors CBLL Competitors EMBC Competitors BBNX Competitors AVNS Competitors BVS Competitors KIDS Competitors RXST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STIM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuronetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
